Title |
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
|
---|---|
Published in |
BMC Gastroenterology, May 2018
|
DOI | 10.1186/s12876-018-0803-1 |
Pubmed ID | |
Authors |
A. Quaas, D. Waldschmidt, H. Alakus, T. Zander, C. Heydt, T. Goeser, M. Daheim, P. Kasper, P. Plum, C. Bruns, A. Brunn, W. Roth, N. Hartmann, A. Bunck, M. Schmidt, H. Göbel, L. Tharun, R. Buettner, S. Merkelbach-Bruse |
Abstract |
Adenocarcinomas or combined adeno-neuroendocrine carcinomas (MANEC) of small bowel usually have a dismal prognosis with limited systemic therapy options. This is the first description of a patient showing a germline-related BRCA1 mutated MANEC of his ileum. The tumor presented a susceptibility to a combined chemotherapy and the PARP1-inhibitor olaparib. A 74-year old male patient presented with a metastasized MANEC of his ileum. Due to clinical symptoms his ileum-tumor and the single brain metastasis were removed. We verified the same pathogenic (class 5) BRCA1 mutation in different tumor locations. There was no known personal history of a previous malignant tumor. Nevertheless we identified his BRCA1 mutation as germline-related. A systemic treatment was started including Gemcitabine followed by selective internal radiotherapy (SIRT) to treat liver metastases and in the further course Capecitabine but this treatment finally failed after 9 months and all liver metastases showed progression. The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. All liver metastases demonstrated with significant tumor regression after 3 months and could be removed. In his most current follow up from December 2017 (25 months after his primary diagnosis) the patient is in a very good general condition without evidence for further metastases. We present first evidence of a therapy susceptible germline-related BRCA1 mutation in small bowel adeno-neuroendocrine carcinoma (MANEC). Our findings offer a personalized treatment option. The germline background was unexpected in a 74-year old man with no previously known tumor burden. We should be aware of the familiar background in tumors of older patients as well. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 18 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 17% |
Student > Doctoral Student | 2 | 11% |
Student > Ph. D. Student | 2 | 11% |
Researcher | 2 | 11% |
Unspecified | 1 | 6% |
Other | 4 | 22% |
Unknown | 4 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 56% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
Unspecified | 1 | 6% |
Agricultural and Biological Sciences | 1 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 6% |
Other | 0 | 0% |
Unknown | 4 | 22% |